Biodesix (BDSX) Shares Outstanding: History & Chart

Biodesix, Inc.(BDSX)

Medical - Diagnostics & Research · Louisville, CO

$28.50-0.56 (-1.93%)

Delayed quote: Oct 6, 2026, 1:14 PM EDT

About Biodesix, Inc.

Biodesix, Inc. is a data-driven diagnostic solutions provider operating across the United States. Its primary focus includes a comprehensive suite of blood-based lung tests, marketed as the Nodify Lung Nodule Risk Assessment (which includes Nodify XL2 and Nodify CDT). These assessments enable clinicians to evaluate the risk of lung cancer in patients with suspicious nodules, aiding in the reclassification of malignancy risk and guiding appropriate treatment pathways. Beyond risk assessment, Biodesix offers additional lung cancer diagnostics such as GeneStrat ddPCR, which detects specific tumor mutations, and VeriStrat, which gauges the patient's immune system status. Both are crucial for establishing prognosis and informing treatment plans. Another offering is the GeneStrat NGS (Next-Generation Sequencing) test, a rapid, blood-based sequencing solution providing results within 72 hours. Through a partnership with Bio-Rad Laboratories, Inc., Biodesix also provides COVID-19 testing services under its Biodesix WorkSafe program, featuring the Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 Total Ab test, an antibody assay for detecting a B-cell immune response indicating recent or prior infection. Furthermore, the company extends its expertise to biopharmaceutical companies, offering diagnostic and clinical research services, alongside clinical trial testing. It also actively discovers, develops, and commercializes companion diagnostics. Originally incorporated as Elston Technologies, Inc. in 2005, Biodesix, Inc. maintains its headquarters in Boulder, Colorado.

Louisville, CO

334 employees

www.biodesix.com

Healthcare / Medical - Diagnostics & Research

Sector: Healthcare
Industry: Medical - Diagnostics & Research
CEO: Scott Hutton

View full financials

Latest FMP share-count observation

Shares outstanding

8,140,279

Float shares

4,656,910

Source: FMP shares-float. FMP feed updated 2026-10-05 20:22:45 (timezone not supplied). The feed does not specify the effective date of this share count.

Shares outstanding measure the share count in the provider observation. Basic and diluted weighted averages below are EPS calculation inputs. Differences between these counts do not measure new issuance or buybacks.

Weighted-average shares by quarterly statement

FMP normalized EPS denominators, labeled by statement period end. These are weighted averages, not current shares outstanding. The provider's period duration may include year-to-date values.

Statement period	Period end	Weighted average basic shares	Weighted average diluted shares
Q2 FY2026	2026-06-30	10,296,000	10,296,000
Q1 FY2026	2026-03-31	9,656,000	9,656,000
Q4 FY2025	2025-12-31	8,064,999	8,064,999
Q3 FY2025	2025-09-30	7,500,000	7,500,000
Q2 FY2025	2025-06-30	7,332,800	7,332,800
Q1 FY2025	2025-03-31	7,327,350	7,327,350
Q4 FY2024	2024-12-31	7,330,150	7,330,150
Q3 FY2024	2024-09-30	7,314,800	7,314,800
Q2 FY2024	2024-06-30	6,358,400

Weighted-average shares by annual statement

FMP normalized EPS denominators, labeled by statement period end. These are weighted averages, not current shares outstanding. The provider's period duration may include year-to-date values.

Statement period	Period end	Weighted average basic shares	Weighted average diluted shares
2025	2025-12-31	7,551,000	7,551,000
2024	2024-12-31	6,483,500	6,483,500
2023	2023-12-31	4,105,650	4,105,650
2022	2022-12-31	2,105,150	2,105,150
2021	2021-12-31	1,368,250	1,368,250
2020	2020-12-31	1,328,075	1,328,075
2019	2019-12-31	1,328,075	1,328,075
2018	2018-12-31	1,327,065	1,327,065

Shares Outstanding: 8,140,279

Latest FMP share-count observation

BDSX Weighted Average Basic Shares

BDSX Weighted Average Diluted Shares

Weighted-average shares by quarterly statement

Weighted-average shares by annual statement